Zoetis Inc. (NYSE:ZTS) Receives Average Recommendation of “Buy” from Analysts

Zoetis Inc. (NYSE:ZTS) has received an average recommendation of “Buy” from the ten research firms that are presently covering the company, Marketbeat reports. Nine equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. The average 12-month target price among brokerages that have covered the stock in the last year is $221.44.

ZTS has been the subject of a number of recent research reports. Piper Sandler lifted their price objective on shares of Zoetis from $195.00 to $210.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 14th. Argus upgraded Zoetis to a “strong-buy” rating in a research report on Friday, August 9th. BTIG Research upped their price objective on Zoetis from $220.00 to $225.00 and gave the company a “buy” rating in a research report on Monday, August 12th. JPMorgan Chase & Co. lifted their target price on Zoetis from $225.00 to $230.00 and gave the stock an “overweight” rating in a report on Friday, October 11th. Finally, Stifel Nicolaus raised their price target on Zoetis from $200.00 to $210.00 and gave the stock a “buy” rating in a research report on Wednesday, September 18th.

Zoetis Trading Up 0.1 %

Shares of NYSE:ZTS opened at $176.96 on Monday. The stock’s fifty day moving average price is $185.62 and its 200-day moving average price is $180.72. The company has a debt-to-equity ratio of 1.26, a current ratio of 3.69 and a quick ratio of 2.27. The company has a market cap of $79.84 billion, a P/E ratio of 33.26, a PEG ratio of 2.71 and a beta of 0.90. Zoetis has a 1 year low of $144.80 and a 1 year high of $201.92.

Zoetis (NYSE:ZTS) last posted its quarterly earnings data on Monday, November 4th. The company reported $1.58 EPS for the quarter, topping the consensus estimate of $1.46 by $0.12. Zoetis had a return on equity of 51.98% and a net margin of 26.55%. The firm had revenue of $2.40 billion during the quarter, compared to analyst estimates of $2.29 billion. During the same period in the prior year, the business posted $1.36 EPS. Zoetis’s revenue was up 11.6% on a year-over-year basis. Sell-side analysts expect that Zoetis will post 5.9 earnings per share for the current year.

Zoetis Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, December 3rd. Investors of record on Thursday, October 31st will be given a dividend of $0.432 per share. This represents a $1.73 annualized dividend and a dividend yield of 0.98%. The ex-dividend date is Thursday, October 31st. Zoetis’s payout ratio is 32.52%.

Institutional Trading of Zoetis

Several large investors have recently bought and sold shares of ZTS. Darwin Wealth Management LLC acquired a new position in shares of Zoetis during the 3rd quarter valued at about $31,000. First Personal Financial Services purchased a new position in Zoetis during the third quarter worth about $33,000. Capital Performance Advisors LLP acquired a new position in Zoetis in the 3rd quarter valued at about $33,000. Dunhill Financial LLC grew its stake in shares of Zoetis by 80.6% in the 3rd quarter. Dunhill Financial LLC now owns 168 shares of the company’s stock valued at $33,000 after buying an additional 75 shares during the period. Finally, Quarry LP increased its holdings in shares of Zoetis by 273.2% during the 2nd quarter. Quarry LP now owns 209 shares of the company’s stock worth $36,000 after buying an additional 153 shares during the last quarter. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.